Hepatocellular carcinoma systemic treatment update: From early to advanced stage.

Biomed J · 2025 · PMC12414342 · PMID 39561966

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The phase III KEYNOTE-240 trial revealed that pembrolizumab did not reach statistical significance in the OS and PFS when compared with placebo, possibly because of its overly aggressive statistical hypothesis.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.